Page 1256 - Veterinary Toxicology, Basic and Clinical Principles, 3rd Edition

Index 1187

VetBooks.ir 3,4-Methylenedioxy-N-ethylamphetamine Micruroides euryxanthus. See Sonoran coral MMR. See Mismatch repair (MMR)
Model validation, 141
snake (Micruroides euryxanthus)
(MDEA), 397
Milbemycin, 539, 541f, 545t
Methylenedioxyamphetamine (MDMA), 198,
MOE. See Margin of exposure (MOE)
385, 395, 399 400
Molluscicide metaldehyde, 234 235
Military nerve agents, 82 85
7,8-Methylenedioxylycoctonine (MDL), 230, Military agents, 71 Moisture management of grain, 985 986
848 LD 50 for, 84t Molybdenum (Mo), 463, 941 942
MDL-type alkaloids, 848 mechanism of action, 83 deficiency, 463
Methylenedioxypyrovalerone (MDPV), pharmacokinetics/toxicokinetics, 83 mechanism of action, 464 465
399 401 toxicity, 83 84 pharmacokinetics/toxicokinetics
N,N’-[(Methylimino)dimethylidyne]di-2,4- treatment, 84 85 absorption, 463 464
xylidine. See Amitraz Milk distribution, 464
Methyllycaconitine (MLA), 848 850 aflatoxins in, 988 elimination, 464
Methylmercury (meHg), 455, 457 458, 726, sickness, 867 toxicity, 463, 465
736 737 Milkvetches. See Nitro-containing Astragalus treatment, 465 466
4-Methylmethcathinone. See Mephedrone Milkweeds (Asclepias spp.), 228, 879 880 MON. See Moniliformin (MON)
Methylphenidate, 395, 397 common name, distribution, habitat, and Monensin, 233, 720, 1073 1075, 1074f,
Methylphenobarbital, 390 toxin, 881t 1077 1078
4-Methylpyrazole (4MP). See Fomepizole distribution and habitat, 880 cardiovascular effects, 1076
N-(Methylsuccinimido) anthranoyllycoctonine toxicology, 880 881 cation ion exchange diffusion, 1077f
(MSAL), 848 treatment and control, 882 clinical signs in beef cattle, 1082t
Methylsuccinyl anthranoyllycoctonine Millipedes, 785 786 facilitating cation exchange diffusion, 1079
(MSAL), 230 Milvus milvus. See Red kites (Milvus milvus) effect of feeding, 1082t
Methylxanthines, 357, 389 390 Minamata disease, 455 general pharmacology studies, 1075t
Metolcarb, 496, 502t MINChar initiative. See Minimum Information LD 50 , 1080 1081
Metronidazole, 199 on Nanoparticle Characterization sequence of events, 1078f
Mexacarbate, 496, 502t initiative (MINChar initiative) Moniliformin (MON), 737
Mexican beaded lizard, 796 Mineral Cationic Carrier (MCC), 76 Monkey grass. See Equisetum spp. (Horsetail
MFOs. See Mixed function oxidases (MFOs) Mineral(s), 357 family)
MgO. See Magnesium oxide (MgO) antacids, 378 379, 379t Monkshood, 230 231, 901
MI. See 3-Methyl indole (MI) oil, 1148 Monoamine oxidase (MAO), 202, 398, 526
MI complexes. See Metabolite inhibitory Minimal Risk Levels (MRLs), 28 Monogastric animals, 425, 485
complexes (MI complexes) Minimum Information on Nanoparticle Monogastrics, 470 471
MIC calculation (MICcalc), 109 Characterization initiative (MINChar Monograph program, 12
Michaelis Menton equations, 139 initiative), 321 Monomethylhydrazine, 959
Michigan, PBB incident in, 677 678 Minimum lethal dose (MLD), 649, 950 Mononuclear leukocytes, 1045
Microarrays, 165 Minimum required performance limits Monte Carlo method, 141, 141f
Microbial metabolism, 1044 1045 (MRPLs), 113, 113t Monteban. See Narasin
Microbiological ADI (mADI), 109, 109f Minipigs, 149 Morphine, 393, 505
Microcystins, 764 770, 765f Minke whales (Balaenoptera acutorostrata), Morphine sulfate, 392
mechanism of action, 768 769 798 Morpholines, 577
pharmacokinetics/toxicokinetics, 768 Mipafox. See Phosphorodiamidic fluoride Morula, 292 293
toxicity, 769 miR 155. See microRNA 155 (miR 155) Motor oil, 661
treatment, 769 770 miRNA. See microRNA (miRNA) Mountain gorillas of Rwanda, 936 937
Microcystis aeurginosa (M. aeurginosa), 712 MIS. See Mu ¨llerian inhibiting substance (MIS) Mouse spot test, 149
Microcystis genera, 712, 770 Miserotoxin. See Glycoside(s) Mouse unit (MU), 745
microRNA (miRNA), 351 352 Mismatch repair (MMR), 347 348 Moxidectin, 539, 541, 542f, 545t
microRNA 155 (miR 155), 537 Misoprostol, 369 MPT. See Mitochondrial permeability
Microscopic lesions, 413, 860, 870, 876 Mistletoe, 893 transition (MPT)
Microscopic pathology Mitochondria, 251 252 MPU. See Median paralysis unit (MPU)
differential diagnosis, 991 Mitochondrial damage, 251 MR. See Metastatic rate (MR)
edema, 991 Mitochondrial DNA, 251 MRLs. See Maximum residue limits (MRLs);
hemorrhage, 991 Mitochondrial injury, 251 252 Minimal Risk Levels (MRLs)
hepatic lesions, 991 Mitochondrial permeability transition (MPT), MRPLs. See Minimum required performance
other lesions, 991 251, 447 448 limits (MRPLs)
Microsomal enzymes, 244 Mitogen-activated protein kinase (MAPK), MRPS. See Multidrug resistance-associated
Microsomal P450 enzymes, 391 219, 276, 824, 1045 proteins (MRPS)
Microsomes, 244 Mitosis. See Proliferation phase of MS. See Mass spectrometry (MS)
Microtiter plate format, 155 spermatogenesis MS/MS. See Tandem mass spectrometry (MS/
Microtus arvalis. See Common voles (Microtus Mixed function oxidases (MFOs), 510 511 MS)
arvalis) Mixed neurotransmitter effects, 205 206 MSAL. See N-(Methylsuccinimido)
Microtus brandti. See Brandt’s vole (Microtus MLA. See Methyllycaconitine (MLA) anthranoyllycoctonine (MSAL);
brandti) MLD. See Minimum lethal dose (MLD) Methylsuccinyl anthranoyllycoctonine
Microvesicular steatosis, 247 MLs. See Macrocyclic lactone endectocides (MSAL)
Microwave digestion, 1121 (MLs) MSNs. See Medium spiny neurons (MSNs)